Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trazodone is an oral antidepressant medication belonging to the phenylpiperazine class. It is classified as a serotonin antagonist and reuptake inhibitor (SARI). Trazodone is primarily used to treat major depressive disorder and can also be prescribed for anxiety disorders and insomnia. It works by modulating serotonin activity in the brain to help restore mental balance. Due to its sedative effects, it is sometimes used off-label for sleep disturbances. Common side effects include dry mouth, dizziness, vomiting, headache; more serious side effects may include suicidal thoughts or behaviors (especially in young people), mania or hypomania in bipolar disorder patients, irregular heart rate (arrhythmia), and priapism (prolonged erection). The drug was approved for medical use in the United States in 1981[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trazodone.